Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those ...

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The Purchaser Business Group on Health said self-funded employers could use its data-powered tool to construct provider ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Peanut butter, cinnamon, dark chocolate chip, salted caramel — the flavors go on and on. Protein bars are definitely tasty.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...